Clinician reference
Working reference tables for the questions that come up at the desk, on rounds, and in the middle of a med reconciliation. Built for nurse practitioners, psychiatry residents, and any prescriber who wants a fast, sourced look at what the guidelines actually say. Everything here is reviewed by a board-certified psychiatrist and current as of June 8, 2026.
Nothing on this page is medical advice. It's a study and reference resource. Every decision belongs with the licensed clinician who knows the patient.
Drug interactions and metabolism
The two questions every clinician asks first: what does this drug interact with, and how long does it stick around.
- Reference table CYP450 psychiatric interactions Substrate, inhibitor, and inducer status for every psych med, grouped by CYP enzyme, with the clinical scenarios that actually matter (fluvoxamine and clozapine, carbamazepine as an inducer, fluoxetine and tamoxifen, and more).
- Reference table Half-life quick reference Half-lives across SSRIs, SNRIs, antipsychotics, benzodiazepines, mood stabilizers, and stimulants, with how that shapes taper speed and discontinuation risk.
Dosing in special populations
When kidney, liver, age, or pregnancy changes the answer.
- Reference table Renal dosing in psychiatric meds Which meds to avoid, which to dose-adjust, and which are safest by eGFR band. Lithium, gabapentin, pregabalin, venlafaxine, paliperidone, duloxetine, and more.
- Reference table Hepatic dosing in psychiatric meds By Child-Pugh class, plus the LFT-friendly picks: lorazepam, oxazepam, temazepam, and where valproate, atomoxetine, duloxetine, and naltrexone don't fit.
- Reference table Beers Criteria: psychiatric meds Which psych meds the 2023 Beers Criteria flag in older adults, why, and safer alternatives. Includes STOPP/START v3 notes.
- Reference table Pregnancy and lactation safety A working framework for pregnancy and breastfeeding decisions across antidepressants, mood stabilizers, antipsychotics, benzodiazepines, and stimulants, with LactMed pointers.
Dose equivalents
The tables you actually use during a switch.
- Equivalence table Antipsychotic CPZ equivalents Chlorpromazine-equivalent dosing across typicals and atypicals, plus WHO DDD reference. Useful when converting between drugs or reading older literature.
- Equivalence table Benzodiazepine equivalents Diazepam-equivalent doses, half-lives, and onset. The table for cross-tapers and inpatient conversions.
Switching and stopping
The moves that go wrong most often.
- Decision guide Antidepressant switching and cross-taper Direct-switch table, cross-taper matrix, MAOI washouts, and the drugs (fluoxetine, paroxetine, venlafaxine) that need special handling.
- Decision guide Antipsychotic switching Cross-taper, plateau, and abrupt-switch strategies. When to overlap, when to pause, and the classes where withdrawal dyskinesia or rebound psychosis is a risk.
- Recognition guide Discontinuation syndromes SSRI/SNRI discontinuation, benzodiazepine withdrawal, stimulant hold, antipsychotic withdrawal dyskinesia, and lithium rebound. Recognition and management.
Comorbidity-based selection
Picking the med that fits the whole patient, not just the diagnosis.
How to use these
Every table is built from the same source material as the drug pages on this site: FDA prescribing information, NICE and APA practice guidelines, the ADA/APA metabolic monitoring standard, ISBD lithium consensus, AAPP clozapine guidance, ASAM addiction medicine, Beers Criteria 2023, STOPP/START v3, and Cochrane reviews. Where a specific paper drives a decision (metformin co-commencement per Carolan, clozapine ANC monitoring after the FDA REMS elimination), it's cited on the page.
These pages will keep expanding. If a reference table you rely on isn't here yet, that's a gap to fix and not a decision to leave it out.